Published in Gene Therapy Weekly, July 25th, 2002
The collaboration will focus on the use of ProdiGene's proprietary transgenic plant system and FibroGen's proprietary methods for the production of a large quantity, low-cost source of FibroGen's high quality recombinant gelatin.
Concerns surrounding animal and human-derived proteins make ProdiGene's expertise in the area of recombinant protein production in plants attractive to FibroGen. ProdiGene's technologies have led to ProdiGene's previously announced scale-up to production level quantities of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.